For example, bortezomib and ibrutinib are in trials for patients affected by ABC DLBCL, while EZH2 and BCL6 inhibitors may be used for other patients affected for GCB DLBCL. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.